MitoCareX Bio
Novel Therapies for Hard-to-treat Resistant Cancers
Company Overview
Snapshot
Founded in February 2022 by Alon Silberman, MitoCareX Bio operates with 1–10 employees. The company was acquired by N2OFF in March 2025, marking a significant milestone in its trajectory.
Business overview
MitoCareX Bio is a drug discovery company focused on developing novel therapies for challenging resistant cancers, particularly lung cancer, by targeting mitochondrial transporters (SLC25 protein family). The company leverages its proprietary MITOLINE algorithm and advanced computational capabilities to generate reliable 3D models of mitochondrial proteins, facilitating computer-aided drug discovery (CADD). Its cloud-based computational platform efficiently screens small molecules to identify potential drug candidates, which are then advanced through preclinical development. MitoCareX Bio operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In January 2025, MitoCareX Bio expanded its research efforts to include pancreatic cancer, following positive initial in-vitro results. This strategic expansion signals the company's potential to broaden its therapeutic pipeline beyond lung cancer, indicating a promising growth trajectory and the versatility of its drug discovery platform for other hard-to-treat cancers.
Log in to access full profile ›Company Intelligence Q&A
- What is MitoCareX Bio's primary focus in drug discovery?
- MitoCareX Bio primarily focuses on discovering and developing novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
- When was MitoCareX Bio founded and by whom?
- MitoCareX Bio was founded in February 2022 by Alon Silberman.
- What is the key technology used by MitoCareX Bio for drug discovery?
- MitoCareX Bio utilizes its proprietary MITOLINE algorithm and advanced computational capabilities to generate reliable 3D models for mitochondrial proteins, facilitating the screening of small molecules for drug candidates.
- What was a significant corporate development for MitoCareX Bio in 2025?
- In March 2025, MitoCareX Bio was acquired by N2OFF, Inc. to expand its cancer therapeutics portfolio.
- Has MitoCareX Bio expanded its research beyond lung cancer?
- Yes, in January 2025, MitoCareX Bio expanded its research to pancreatic cancer following initial positive in-vitro results.